Journal
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Volume 59, Issue 45, Pages 19787-19795Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.202008879
Keywords
biological barrier; GI tract; insulin; oral delivery
Categories
Funding
- U.S. METAvivor Early Career Investigator Award, Harvard Medical School/Brigham
- Women's Hospital Department of AnesthesiologyBasic Scientist Grant, Center for Nanomedicine Research Fund
- Khoury Innovation Award
- American Heart Association (AHA) Collaborative Sciences Award
Ask authors/readers for more resources
Diabetes mellitus is a lifelong metabolic disease that requires frequent subcutaneous injections of insulin. However, this method of administration can be associated with patient discomfort and local tissue infection. Oral delivery of insulin has been pursued as a more convenient method for diabetes treatment, given its likely superior patient compliance and convenience as well as cost-effectiveness. However, various biological barriers hinder the clinical translation of oral insulin. The rapid development of nanotechnology over the last decade offers great promise in improving the bioavailability of oral insulin. This Minireview provides an overview of biological barriers to oral insulin delivery, summarizes significant technological advances, and outlines future perspectives in oral insulin formulations as well as their hypoglycaemic effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available